Humatrope Enhances Growth in American Males with Noonan Syndrome: 7-Year Trial Results
Reading Time: 2 minutes Introduction Noonan Syndrome, a genetic disorder characterized by distinctive facial features, heart defects, and short stature, poses significant challenges to affected individuals, particularly in terms of growth and development. In the United States, where the prevalence of Noonan Syndrome is estimated to be between 1 in 1,000 to 1 in 2,500 live births, the impact on American males can be particularly pronounced. This article delves into a comprehensive 7-year randomized controlled trial that investigated the efficacy of Humatrope, a recombinant human growth hormone, in enhancing growth outcomes in American males diagnosed with Noonan Syndrome. Study Design and Methodology The study...


